Linaclotide Segment of Peptide Based Gastrointestinal Disorders Therapeutics Underpins Demand Upsurge
Prevalence of diverse gastrointestinal ailments such as bowel disorders and chronic constipation have instigated adoption of novel therapeutics to attain considerable relief. Several biopharmaceutical companies have invested massively towards development of their pipeline portfolios, thereby fostering reasonable progress in peptide based gastrointestinal disorders therapeutics. Strategic coalitions with premiere research institutes as well as parallel partnership amongst pharmaceutical companies favoring novel drug innovations is one of the foremost trends in peptide based gastrointestinal disorders therapeutics market.
View full press release